What is included in the long-term monitoring of acute myeloid leukemia (AML)?

Updated: May 26, 2020
  • Author: Karen Seiter, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print
Answer

Patients should come to the office for monitoring of disease status and chemotherapy effects. Guidelines from the National Comprehensive Cancer Network (NCCN) recommend that after completion of consolidation therapy for AML, patients should undergo surveillance with a complete blood cell count every 1–3 months for 2 years, then every 3–6 months up to 5 years. The NCCN recommends a bone marrow aspirate and biopsy only if a peripheral smear is abnormal or cytopenias develop. [25]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!